To test the efficacy of ABBV-221, an epidermal growth factor receptor (EGFR) inhibitor, administered intravenously with blood-brain-barrier (BBB) opening in murine models of glioblastoma (GBM) to ascertain if this delivery strategy prolongs survival.
|Effective start/end date||3/25/22 → 3/24/23|
- AbbVie Inc. (Heimberger AGMT 4/8/22)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.